NIH Panel Releases New Statement on Therapies for High-Risk, Non-Hospitalized Patients

January 20, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has added a new statement to the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

Because the anti-SARS-CoV-2 monoclonal antibodies (mAbs) bamlanivimab plus etesevimab and casirivimab plus imdevimab are predicted to have markedly reduced activities against the Omicron variant, and because real-time testing to identify rare, non-Omicron variants is not routinely available, the Panel recommends against the use of these anti-SARS-CoV-2 mAbs.

For complete details, please see the full update on the COVID-19 Treatment Guidelines website.